Verve Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Verve Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Verve Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$58.8M, a 0.44% decline year-over-year.
  • Verve Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$222M, a 6.5% decline year-over-year.
  • Verve Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$223M, a 34.7% decline from 2022.
  • Verve Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$166M, a 90.3% decline from 2021.
  • Verve Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$87.1M, a 114% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$223M -$57.4M -34.7% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 -$166M -$78.6M -90.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 -$87.1M -$46.4M -114% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 -$40.6M -$27M -198% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-02
2019 -$13.6M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.